No black box warning on record for Defencath

As of the latest FDA labeling reviewed, Defencath (TAUROLIDINE AND HEPARIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Defencath medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Heparin-Induced Thrombocytopenia (HIT) : HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures. ( 5.1 ) Drug Hypersensitivity Reactions : Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% i

No black box warning on record for Defencath

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Heparin-Induced Thrombocytopenia (HIT) : HIT was reported in Trial 1 at an incidence rate of 0.3% in patients using heparin, a component of DEFENCATH as a CLS. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures. ( 5.1 ) Drug Hypersensitivity Reactions : Drug hypersensitivity reactions were reported in Trial 1 at an incidence rate of 0.5% i

Defencath Black Box Warning

No black box warning on record for Defencath

Other warnings & precautions

Defencath Black Box Warning

No black box warning on record for Defencath

Other warnings & precautions